Irinotecan Sun (Irinotecan Hydrochloride Trihydrate)

• Irinotecan Sun is a Topoisomerase I inhibitor used in colorectal cancer treatment pathways.
• Metastatic colorectal cancer: improves overall survival when combined with fluoropyrimidine‑based regimens.
• Adjuvant therapy for colon cancer: reduces risk of disease recurrence after surgical resection.
• Locally advanced colorectal cancer: may be employed in neoadjuvant protocols to shrink tumors before surgery.

• Irinotecan is a pro‑drug that is converted intracellularly to SN‑38, a potent inhibitor of topoisomerase I. By stabilising the enzyme‑DNA complex, it prevents relegation of single‑strand DNA breaks during replication, leading to accumulation of DNA damage and ultimately tumor cell apoptosis.

Irinotecan Sun may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Diarrhea: often severe and may require antidiarrheal therapy.
• Neutropenia: reduced white blood cell count increasing infection risk.
• Nausea and vomiting: may be managed with antiemetics.
• Alopecia: temporary hair loss.
• Fatigue: generalized tiredness during treatment.
• Abdominal cramping: discomfort in the stomach area.

Serious or Rare Side Effects

• Febrile neutropenia: fever with low neutrophil count requiring urgent care.
• Severe colitis: inflammation of the colon that can be life‑threatening.
• Hepatotoxicity: elevated liver enzymes indicating liver injury.
• Hypersensitivity reactions: rash, bronchospasm, or anaphylaxis.
• Hemorrhagic cystitis: bladder inflammation with bleeding.
• Cardiotoxicity: rare cardiac dysfunction or arrhythmias.

Before initiating Irinotecan Sun, clinicians should assess patient suitability and monitor for known risks.

• Baseline blood counts: obtain complete blood count to detect pre‑existing neutropenia.
• Liver function: evaluate hepatic enzymes as impaired function can increase toxicity.
• Renal function: adjust monitoring for patients with reduced clearance.
• Concomitant medications: review for agents that may exacerbate myelosuppression.
• Pregnancy and lactation: avoid use unless benefits clearly outweigh potential fetal or infant risks.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Irinotecan Sun can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce SN‑38 exposure.
• Anticholinergic agents (e.g., atropine, scopolamine): increase risk of severe diarrhea.
• High‑dose corticosteroids: may potentiate neutropenia.

Moderate Interactions (Monitor Closely)

• Moderate CYP3A4 inhibitors (e.g., fluconazole, erythromycin): may raise SN‑38 levels.
• Warfarin: monitor INR as Irinotecan can affect coagulation.
• UGT1A1 polymorphisms: genetic testing may be warranted to adjust dosing.